Leavell Investment Management Inc. trimmed its position in Baxter International Inc (NYSE:BAX) by 1.1% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 13,429 shares of the medical instruments supplier’s stock after selling 149 shares during the quarter. Leavell Investment Management Inc.’s holdings in Baxter International were worth $1,094,000 as of its most recent SEC filing.
Other hedge funds have also recently modified their holdings of the company. Gantzert Investment Co. LLC ADV purchased a new stake in shares of Baxter International in the 4th quarter worth $25,000. Parisi Gray Wealth Management purchased a new stake in shares of Baxter International in the 4th quarter worth $26,000. Sontag Advisory LLC purchased a new stake in shares of Baxter International in the 4th quarter worth $30,000. Baldwin Brothers Inc. MA lifted its holdings in shares of Baxter International by 904.0% in the 4th quarter. Baldwin Brothers Inc. MA now owns 502 shares of the medical instruments supplier’s stock worth $33,000 after buying an additional 452 shares during the period. Finally, We Are One Seven LLC purchased a new stake in shares of Baxter International in the 4th quarter worth $34,000. Institutional investors and hedge funds own 86.45% of the company’s stock.
In other news, Director Peter S. Hellman sold 5,680 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $81.89, for a total value of $465,135.20. Following the transaction, the director now owns 28,774 shares in the company, valued at $2,356,302.86. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Thomas T. Stallkamp sold 3,187 shares of the firm’s stock in a transaction that occurred on Friday, January 18th. The shares were sold at an average price of $70.00, for a total value of $223,090.00. Following the completion of the transaction, the director now owns 9,418 shares in the company, valued at approximately $659,260. The disclosure for this sale can be found here. Insiders sold 98,286 shares of company stock worth $7,399,039 in the last 90 days. Company insiders own 0.70% of the company’s stock.
Baxter International (NYSE:BAX) last issued its earnings results on Thursday, January 31st. The medical instruments supplier reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Baxter International had a return on equity of 19.10% and a net margin of 14.60%. The firm had revenue of $2.84 billion for the quarter, compared to the consensus estimate of $2.80 billion. On average, research analysts predict that Baxter International Inc will post 3.27 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Monday, April 1st. Stockholders of record on Friday, March 1st were paid a $0.19 dividend. The ex-dividend date was Thursday, February 28th. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.98%. Baxter International’s payout ratio is 24.92%.
Several equities research analysts have weighed in on the company. Barclays upped their target price on Baxter International from $72.00 to $75.00 and gave the stock an “equal weight” rating in a report on Monday. Wells Fargo & Co boosted their price target on Baxter International from $80.00 to $89.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 3rd. Zacks Investment Research lowered Baxter International from a “buy” rating to a “hold” rating in a research report on Tuesday, April 2nd. Morgan Stanley boosted their price target on Baxter International from $80.00 to $83.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 5th. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $80.00 price objective on shares of Baxter International in a report on Friday, February 1st. Four research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $78.31.
TRADEMARK VIOLATION WARNING: “Leavell Investment Management Inc. Lowers Holdings in Baxter International Inc (BAX)” was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/4299293/leavell-investment-management-inc-lowers-holdings-in-baxter-international-inc-bax.html.
About Baxter International
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Featured Article: Systematic Risk
Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.